The MCTRC, in partnership with the Quebec – Clinical Research Organization in Cancer (Q-CROC), implements investigator-initiated biopsy-driven translational research, via its clinical research infrastructure. The overall aim is to identify molecular signatures and mechanisms of resistance to particular treatment in the clinical setting. Researchers involved in the biomarker/biopsy-driven research group apply OMIC technologies to look at hundreds of thousands of genes, proteins and other compounds simultaneously to identify biomarkers and molecular signatures associated with disease type, stage and outcome of cancer treatment.
Theme leader:
Dr. Gerald Batist, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Members:
Dr. Moulay Alaoui-Jamali, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Sarit Assouline, Jewish General Hospital, Ï㽶ÊÓƵ
Dr. Mark Basik, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Christoph Borchers, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Cristiano Ferrario, Jewish General Hospital, Ï㽶ÊÓƵ
Dr. Walter Gotlieb, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Celia Greenwood, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Nathalie Johnson, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Claudia Kleinman, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Bernard Lesperance, Université de Montréal
Dr. Wilson Miller, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
Dr. Alan Spatz, Lady Davis Institute for Medical Research, Ï㽶ÊÓƵ
